// App-Quantinova.ai

e14567 : Bevacizumab plus temsirolimus as second-line treatment for advanced hepatocellular carcinoma (HCC).

Researchers

Presenter

  • Leonidas Chelis

Principal Investigators

  • Savas Deftereos

  • Nikolaos Xenidis

  • Stylianos Kakolyris

  • Kiriakos Amarantidis

  • Eleni Kyrillos Hamalidou

  • Prokopios Dimopoulos

  • Prodromos Michailidis

  • Evagelos Christakidis

  • Kostantinos Mimidis

  • Dimitra Pitsiava

  • Anastasios Karayiannakis

Medical Centers

  • Department of Medical Oncology, University Hospital of Alexandroupoli, Alexandroupoli, AZ, Greece

  • First Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece

  • Second Department of Surgery, Democritus University of Thrace, Alexandroupolis, Greece

  • Department of Medical Oncology, University Hospital of Alexandroupoli, Alexandroupoli, AZ, Greece

Locations

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Alpha-fetoprotein

  • Hepatocyte growth factor

  • Thrombospondin-1

  • Vascular endothelial growth factor A

Drug/Treatment

  • Temsirolimus

  • Bevacizumab

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved